Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb;10(2):753-765.
doi: 10.21037/tlcr-20-559.

Exon 20 YVMA insertion is associated with high incidence of brain metastasis and inferior outcome of chemotherapy in advanced non-small cell lung cancer patients with HER2 kinase domain mutations

Shuo Yang  1 , Yan Wang  1 , Chao Zhao  2 , Xuefei Li  2 , Qian Liu  1 , Shiqi Mao  1 , Yiwei Liu  1 , Xiaofei Yu  1 , Wanying Wang  1 , Qinrun Tian  1 , Yingying Pan  1 , Anwen Xiong  1 , Bin Chen  1 , Guanghui Gao  1 , Wei Li  1 , Yayi He  1 , Fengying Wu  1 , Xiaoxia Chen  1 , Chunxia Su  1 , Shengxiang Ren  1 , Caicun Zhou  1
Affiliations

Exon 20 YVMA insertion is associated with high incidence of brain metastasis and inferior outcome of chemotherapy in advanced non-small cell lung cancer patients with HER2 kinase domain mutations

Shuo Yang et al. Transl Lung Cancer Res. 2021 Feb.

Abstract

Background: Chemotherapy remains the standard care for HER2 mutated advanced non-small cell lung cancer (NSCLC) even though several targeted drugs showed promising results in preliminary stages. This study aimed to investigate the association of mutation variants with clinical features and the efficacy of chemotherapy in patients with HER2 mutated advanced NSCLC.

Methods: ARMS-PCR was used to identify HER2 mutation in patients without common oncogenic alterations. Patients with detailed information were further enrolled for analysis of clinical features and efficacy of first line chemotherapy. Survival data was analyzed by Kaplan-Meier method and compared by log-rank test. Brain metastasis incidence was analyzed and compared by Gray's test.

Results: YVMA insertion accounted for the majority (68.4%, 67/98) of HER2 mutation, and associated with significantly higher incidence of baseline extrathoracic metastasis (P=0.009), notably brain metastasis (P=0.004). Among 82 patients those received first line chemotherapy, YVMA insertion remarkably associated with inferior treatment outcomes, namely, a significantly shorter median progression free survival (PFS) and lower objective response rate (ORR) both in total patients (PFS: 5.2 vs. 7.7 m, P=0.038; ORR: 30.9% vs. 51.9%, P=0.09) and pemetrexed subgroup (PFS: 5.2 vs. 6.5 m, P=0.022; ORR: 31.8% vs. 60.0%, P=0.054). Multivariate analysis further established YVMA insertion as prognostic factor of worse PFS both for total patients (HR =1.578, 95% CI, 0.956-2.606) and patients received pemetrexed-based chemotherapy (HR =1.789, 95% CI, 1.013-3.160). In addition, YVMA insertion associated with higher incidence of lifetime brain metastasis (P=0.002) compared by Gray's test, with estimated 12-month brain metastasis incidence as 40.2% compared with 3.6% in the non-YVMA group.

Conclusions: YVMA insertion is associated with a higher incidence of brain metastasis, and inferior outcomes to chemotherapy than non-YVMA variants in patients with advanced NSCLC and HER2 kinase domain mutations, which emphasized the unmet need of more potent anti-cancer therapies with high blood-brain barrier (BBB) penetration capacity for patients with YVMA insertion.

Keywords: HER2 mutation; YVMA insertion; brain metastasis; chemotherapy; non-small cell lung cancer (NSCLC).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tlcr-20-559). CZ serves as an unpaid editorial board member of Translational Lung Cancer Research from Aug 2020 to Jul 2022. The other authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Flowchart of this study. A total of 98 patients were enrolled for comparison of the baseline clinicopathological features, and 82 patients were enrolled for comparison of the efficacy of first line chemotherapy.
Figure 2
Figure 2
The spectrum of mutation variants of HER2 kinase domain of the enrolled 98 patients.
Figure 3
Figure 3
Comparison of PFS according to HER2 mutation variants. (A) PFS of patients who received chemotherapy as first line treatment (n=82). (B) PFS of patients who received pemetrexed based chemotherapy as first-line treatment (n=64).
Figure 4
Figure 4
Comparison of lifetime brain metastases incidence and cumulative brain metastasis incidence according to HER2 mutation variants in a total of 98 patients. The estimated 12-month brain metastases incidence was also indicated. BM, brain metastasis.
See this image and copyright information in PMC

References

    1. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-42. 10.1016/S1470-2045(11)70184-X - DOI - PubMed
    1. Peters S, Camidge DR, Shaw AT, et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2017;377:829-38. 10.1056/NEJMoa1704795 - DOI - PubMed
    1. Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 2014;371:1963-71. 10.1056/NEJMoa1406766 - DOI - PMC - PubMed
    1. Planchard D, Smit EF, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol 2017;18:1307-16. 10.1016/S1470-2045(17)30679-4 - DOI - PubMed
    1. National Comprehensive Cancer Network. (NCCN) Clinical Practice Guidelines in Oncology. Non-small Cell Lung Cancer, Version 2. 2019. Available online: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed 26 Feb 2019.